查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010005

基因組學市場：按產品類型、技術、應用和最終用戶分類的全球市場預測 - 2026-2032 年

Genomics Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，基因組學市場價值將達到 571.5 億美元，到 2026 年將成長到 626 億美元，到 2032 年將達到 1,122.6 億美元，複合年成長率為 10.12%。

主要市場統計數據
基準年 2025 571.5億美元
預計年份：2026年 626億美元
預測年份 2032 1122.6億美元
複合年成長率 (%) 10.12%

為研究、臨床和商業相關人員制定策略指南，以建立當前的基因組學趨勢、技術考量和關鍵決策。

隨著技術創新、跨領域合作以及監管預期不斷變化，基因組學領域正經歷快速發展，並重塑研究機構、醫療服務提供者和商業公司的策略重點。本文概述了高階主管、研發負責人和採購團隊在評估技術應用、合作機會和資本配置時應考慮的關鍵因素。此外，本文也將這一主題置於轉化科學、供應鏈韌性以及治療方法和診斷領域整體精準醫療日益成長的需求等更廣泛的背景下進行探討。

技術突破、不斷演變的經營模式以及日益成長的監管期望如何重塑基因組學領域的競爭格局和營運重點。

基因組學格局正因技術成熟度、經營模式轉變和新興政策趨勢的相互作用而發生變革，由此產生的結構性變化亟需對現有策略進行重新評估。高通量定序和單細胞分析技術的進步降低了產生複雜資料集的門檻，從而促進了從孤立實驗向整合多體學專案的轉變。這種轉變有利於那些能夠將分析深度與穩健的資料管理和解讀框架結合的機構，使其不僅在處理能力方面脫穎而出，更在可操作的洞見方面實現差異化。

評估 2025 年關稅措施對基因組學企業的籌資策略、供應鏈彈性計畫和供應商風險分配的影響。

關稅和貿易限制等措施的實施會對基因組學生態系統產生多方面的影響，可能波及供應商關係、採購決策以及實驗室運作的成本結構。 2025年實施的關稅促使採購團隊加快重新評估其供應商組合、實現供應商多元化並尋找替代供應商，以確保關鍵設備和耗材的持續供應。這種轉變使得採購團隊更加重視那些擁有穩健製造地和透明關稅減免策略的供應商。

透過對產品、應用、最終用戶和技術等方面進行全面細分分析，指導有針對性的研發、商業化和服務策略。

了解市場區隔對於建立整個基因組學領域的產品開發、商業策略和服務交付模式至關重要。依產品類型分析市場，可以發現微陣列、PCR、試劑和耗材、定序服務以及定序系統等細分市場。微陣列類別進一步細分為基因表現晶片和SNP基因型鑒定晶片，而PCR則分為數位PCR和qPCR。試劑和耗材包括酵素和預混液、樣品製備盒、探針和引子。定序服務包括次世代定序服務和Sanger定序服務。定序系統進一步細分為NGS平台和Sanger測序儀。這種以產品為中心的觀點突顯了創新發生的領域，以及傳統平台生命週期壓力可能推動的再投資或遷移。

區域情報觀點，將美洲、歐洲、中東和非洲以及亞太市場的採用促進因素、監管多樣性和夥伴關係機會連結起來。

區域趨勢在決定整個基因組學生態系統的應用模式、監管路徑和夥伴關係方面發揮著至關重要的作用。在美洲，大規模的集中，催生了對先進定序和精準診斷的需求，同時也促進了商業開發商和臨床採用者之間的密切合作。這種環境加速了從研究創新到臨床檢驗試驗和商業部署的轉化。

以平台整合、服務擴展和策略夥伴關係為中心的供應商策略如何重新定義競爭優勢和客戶維繫。

企業層面的措施正在重塑競爭格局，主要企業正投資於平台整合、服務多元化和策略夥伴關係，以實現超越單一產品銷售的價值。那些將儀器創新與強大的試劑組合和擴充性的服務交付相結合的企業，更有能力提供滿足端到端客戶需求的整合解決方案。此外，對軟體、數據分析和雲端解讀服務的投資，正在創造新的收入來源，並透過持續的服務模式增強客戶留存率。

實際可行的措施，使高階主管能夠加強供應鏈韌性，實現平台互通性，並提供以結果為導向的服務，從而加速採用。

產業領導者必須採取一系列切實可行的應對措施，重點關注供應鏈韌性、平台互通性和以價值主導的客戶參與，以應對不斷變化的基因組學格局。首先，各組織應優先考慮關鍵耗材的雙重採購和本地庫存策略，以減輕貿易政策波動和物流中斷的影響。與主要供應商簽訂多年期合約並投資於供應商可視性工具，可以降低風險並提高營運的可預測性。

採用嚴謹的多源調查方法，結合關鍵相關人員的訪談、技術文獻綜述和分析框架，來檢驗趨勢和策略意義。

為確保全面平衡的觀點，本研究採用了多方面的調查方法，結合了關鍵相關人員的訪談、技術文獻綜述以及對產品和監管趨勢的系統分析。主要活動包括與各儀器和試劑供應商的研發經理、臨床實驗室主任、採購專家和銷售經理進行對話。這些對話旨在深入了解營運挑戰、產品應用促進因素以及應對不斷變化的政策和供應鏈環境的策略性舉措。

一項結論性的綜合分析強調了適應性、技術整合和管治是不斷發展的基因組學生態系統中持續成功的關鍵因素。

總之，該報告重申，基因組學正處於一個轉折點，技術能力、商業性創新和監管控制的交匯點將決定未來的贏家和輸家。那些將投資集中於互通平台、彈性供應鏈和以結果為導向的服務的機構，將建立永續的競爭優勢。此外，積極應對監管和數據管治問題，將加速檢查室成果向臨床和商業性應用的轉化。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 基因組學市場：依產品類型分類

  • 微陣列
    • 基因表現晶片
    • SNP基因型鑒定晶片
  • PCR
    • 數位PCR
    • qPCR
  • 試劑和耗材
    • 酵素和母料
    • 樣品製備工具包
    • 探針和引子
  • 定序服務
    • NGS服務
    • 桑格定序服務
  • 定序系統
    • NGS平台
    • 桑格定序儀

第9章：基因組學市場：依技術分類

  • 陣列技術
    • 利用微陣列進行基因表現分析
    • SNP基因型鑒定晶片
  • DNA定序
    • 次世代定序
    • 桑格定序
  • PCR技術
    • 數位PCR
    • qPCR
  • RNA定序
    • 批量RNA定序
    • 單細胞RNA定序

第10章 基因組學市場：依應用領域分類

  • 農業
    • 動物基因體學
    • 作物基因組學
  • 診斷
    • 癌症基因體學
    • 基因檢測
    • 傳染病檢查
  • 藥物發現和藥物開發
    • 生物標記發現
    • 目標識別
  • 個人化醫療
    • 伴隨診斷
    • 精準治療

第11章 基因組學市場：依最終用戶分類

  • 學術和政府機構
  • 私人研究機構
  • 醫院和診所
  • 製藥和生物技術公司

第12章 基因組學市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 基因組學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 基因組學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國基因組學市場

第16章：中國基因組學市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • Azenta, Inc.
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Color Health, Inc.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Fulgent Genetics, Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Oxford Nanopore Technologies plc
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience Corporation
Product Code: MRR-434CCDA04CD1

The Genomics Market was valued at USD 57.15 billion in 2025 and is projected to grow to USD 62.60 billion in 2026, with a CAGR of 10.12%, reaching USD 112.26 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 57.15 billion
Estimated Year [2026] USD 62.60 billion
Forecast Year [2032] USD 112.26 billion
CAGR (%) 10.12%

A strategic orientation that frames current genomics trends, technology considerations, and critical decisions for research, clinical, and commercial stakeholders

The landscape of genomics continues to evolve rapidly as technological innovation, cross-sector collaboration, and shifting regulatory expectations reshape strategic priorities for research institutions, healthcare providers, and commercial enterprises. This introduction synthesizes the principal drivers that executives, R&D leaders, and procurement teams must consider when evaluating technology adoption, partnership opportunities, and capital allocation. It situates the topic within the broader context of translational science, supply chain resilience, and the intensifying demand for precision approaches across therapeutics and diagnostics.

Emerging sequencing platforms, refinements in PCR modalities, and innovations in microarray design are unlocking new experimental capabilities while simultaneously altering vendor competition and service models. At the same time, applications spanning agriculture to personalized medicine are increasing the number of endpoints and data types that organizations must manage. Consequently, decisions about technology investments and outsourcing relationships are informed not only by instrument performance and reagent quality, but also by integration with bioinformatic pipelines, scalability of sample throughput, and long-term consumables availability.

Against this backdrop, stakeholders must weigh near-term operational needs against longer-term strategic objectives. This report's opening section frames the critical questions: how to prioritize platform selection in the face of heterogeneous use cases, how to mitigate supply and regulatory risks, and how to translate incremental technical advantages into measurable clinical or commercial value. The objective is to orient readers to the levers that will most significantly influence outcomes across research, clinical, and commercial settings.

How converging technology breakthroughs, evolving commercial models, and rising regulatory expectations are reshaping competitive dynamics and operational priorities in genomics

The genomics landscape is being transformed by an interplay of technological maturation, shifting business models, and emergent policy dynamics, producing structural shifts that require recalibrated strategies. Advances in high-throughput sequencing and single-cell capabilities have reduced barriers to generating complex datasets, which in turn is catalyzing a transition from siloed experiments to integrative multi-omic programs. This shift favors organizations that can combine analytical depth with robust data management and interpretation frameworks, thereby creating differentiation through actionable insights rather than raw throughput alone.

Concurrently, the commoditization of certain hardware components and the rise of reagent-focused business models are altering vendor economics and accelerating consolidation in segments where scale matters most. Service providers are expanding offerings to include end-to-end solutions that encompass sample logistics, sequencing, data processing, and regulatory support, thereby appealing to customers seeking simplicity and guaranteed quality. Meanwhile, increased interest in precision agriculture and infectious disease surveillance has broadened the range of end users and created adjacent markets where genomics capabilities can be deployed rapidly.

Finally, ethical and regulatory attention to data privacy, cross-border sample movement, and clinical validation is elevating governance as a competitive dimension. Organizations that proactively integrate compliance, transparent data stewardship, and validated workflows will be better positioned to capture long-term value. These transformative shifts are not isolated; they interact dynamically, meaning that technology choices, commercial partnerships, and compliance strategies must be aligned to navigate the new landscape effectively.

Assessment of how 2025 tariff measures have reshaped procurement strategies, supply chain resilience planning, and vendor risk allocation within genomics operations

The implementation of measures such as tariffs and trade restrictions can generate multi-layered effects on the genomics ecosystem, influencing supplier relationships, sourcing decisions, and cost structures for laboratory operations. Tariffs introduced in 2025 have had the effect of prompting procurement teams to reassess vendor portfolios, diversify sourcing, and accelerate qualification of alternative suppliers to ensure continuity of supply for critical instruments and consumables. This reorientation has placed a premium on suppliers with resilient manufacturing footprints and transparent tariff mitigation strategies.

In practice, organizations have responded by shifting some procurement toward domestically manufactured components or by increasing strategic inventory levels for high-use reagents and consumables. Contractual terms with service providers and instrument vendors have been renegotiated to account for extended lead times and to allocate risk related to cross-border logistics. Additionally, tariff-driven cost pressures have influenced capital expenditure planning, with some purchasers delaying non-essential instrument upgrades while prioritizing consumable availability for ongoing research and clinical workflows.

From a strategic perspective, the tariffs have underscored the importance of supply chain intelligence and scenario planning. Stakeholders are investing in deeper supplier audits, dual-sourcing strategies, and closer collaboration with manufacturers to map production capacity and identify chokepoints. In the medium term, these adaptations could encourage localized manufacturing expansion and longer-term contractual arrangements that provide visibility and predictability despite trade policy volatility. Thus, while tariffs create immediate challenges, they also accelerate structural changes in procurement practices and supply chain design across the genomics sector.

Comprehensive segmentation analysis that maps product, application, end-user, and technology dimensions to guide targeted R&D, commercialization, and service strategies

Understanding market segments is essential to shaping product development, commercial strategy, and service delivery models across the genomics domain. When the market is examined by product type, the analysis spans microarrays, PCR, reagents and consumables, sequencing services, and sequencing systems; the microarrays category further differentiates into gene expression arrays and SNP genotyping arrays, while PCR divides into digital PCR and qPCR; reagents and consumables encompass enzymes and master mixes, library preparation kits, and probes and primers; sequencing services include next-generation sequencing services and Sanger sequencing services; and sequencing systems distinguish between NGS platforms and Sanger sequencers. This product-centric view highlights where innovation is occurring and where lifecycle pressures on legacy platforms may prompt reinvestment or migration.

From an application perspective, the market covers agriculture, diagnostics, drug discovery and development, and personalized medicine. Within agriculture, the focus splits into animal genomics and crop genomics, reflecting differing sample types and analytical requirements. Diagnostics breaks down into cancer genomics, genetic testing, and infectious disease testing, each demanding distinct validation pathways and clinical workflows. Drug discovery and development emphasizes biomarker discovery and target identification, activities that rely on high-throughput, reproducible output. Personalized medicine includes companion diagnostics and precision therapeutics, areas where clinical integration and regulatory alignment are paramount.

Considering end users reveals a spectrum of organizational needs and purchasing behaviors, from academic and government institutes to commercial research organizations, hospitals and clinics, and pharmaceutical and biotechnology companies. These end users vary in procurement sophistication, throughput demands, and tolerance for operational risk. Evaluating the market through the lens of technology highlights the influence of array technology, DNA sequencing, PCR technology, and RNA sequencing. Array technology further divides into microarray gene expression and SNP genotyping arrays; DNA sequencing separates into next-generation sequencing and Sanger sequencing; PCR technology differentiates between digital PCR and qPCR; and RNA sequencing distinguishes bulk RNA sequencing from single-cell RNA sequencing. Together, these segmentation frameworks provide a comprehensive map to align R&D roadmaps, sales strategies, and service design with the nuanced needs of diverse customer cohorts.

A regional intelligence perspective that connects adoption drivers, regulatory diversity, and partnership opportunities across the Americas, EMEA, and Asia-Pacific markets

Regional dynamics play a decisive role in determining adoption patterns, regulatory pathways, and partnership opportunities across the genomics ecosystem. In the Americas, a concentration of large academic centers, integrated healthcare systems, and an active biotechnology sector creates demand for advanced sequencing and precision diagnostics, while fostering close collaboration between commercial developers and clinical implementers. This environment encourages rapid translation of research innovations into clinical validation studies and commercial deployments.

In Europe, Middle East & Africa, the market is characterized by diversity in regulatory frameworks and healthcare delivery models, which in turn affects standardization and cross-border collaboration. The region exhibits strong capabilities in specialized research and translational initiatives, and offers unique opportunities for consortium-based projects that leverage pooled expertise and shared infrastructure. Compliance considerations and national-level reimbursement policies often shape the pace and pathway for clinical adoption.

The Asia-Pacific region demonstrates fast-paced adoption in both academic research and commercial applications, driven by investments in domestic manufacturing, growing clinical sequencing programs, and a rising base of diagnostic laboratories. Local market dynamics, including public health initiatives and agricultural genomics programs, are expanding the addressable applications for genomic technologies. Across regions, variability in reimbursement, regulatory clarity, and manufacturing capacity will continue to influence strategic entry approaches and partnership models, making regional intelligence a critical input for global planning and local execution.

How vendor strategies centered on platform integration, service expansion, and strategic partnerships are redefining competitive advantage and customer retention

Company-level behavior is shaping competitive trajectories, with leading organizations investing in platform integration, service diversification, and strategic partnerships to capture value beyond single-product sales. Firms that combine instrument innovation with robust reagent portfolios and scalable service offerings are better positioned to deliver integrated solutions that meet end-to-end customer needs. Moreover, investments in software, data analytics, and cloud-enabled interpretive services are creating new revenue streams and strengthening customer lock-in through recurring service models.

Strategic alliances and OEM relationships are increasingly common as companies seek to expand addressable markets quickly without duplicating capital expenditures. These collaborations can accelerate time to market for novel assays, enable shared risk for clinical validation, and provide complementary capabilities that enhance total solution value. Meanwhile, mid-sized players and specialized innovators continue to contribute differentiated technologies, particularly in niche applications such as single-cell analytics or novel library preparation chemistries.

Competitive positioning also hinges on operational excellence in supply chain and quality systems. Companies that demonstrate transparent manufacturing practices, robust quality management, and responsive technical support capture trust among high-stakes end users such as clinical laboratories and pharmaceutical developers. Ultimately, the most successful companies will be those that balance technological differentiation with demonstrable customer outcomes and scalable commercial models.

Practical, high-impact actions for executives to enhance supply chain resilience, enable platform interoperability, and deliver outcome-focused services that drive adoption

Industry leaders must adopt a set of actionable responses to navigate the evolving genomics environment, focusing on supply chain resilience, platform interoperability, and value-driven customer engagement. First, organizations should prioritize dual-sourcing and localized inventory strategies for critical consumables to mitigate the effects of trade policy volatility and logistics disruptions. Establishing multi-year agreements with key suppliers and investing in supplier visibility tools will reduce risk and provide operational predictability.

Second, product and services strategies should emphasize interoperability and data portability. Designing instruments and software that facilitate integration with common laboratory information systems and bioinformatics pipelines will lower barriers to adoption and increase the stickiness of commercial relationships. Equally important is an emphasis on outcome-oriented services-packaging analytical capabilities with interpretive reporting and clinical or agronomic insights will differentiate offerings in a crowded marketplace.

Finally, leaders should invest in regulatory readiness and transparent data governance practices. Proactively engaging with regulatory authorities, adopting best-practice validation protocols, and demonstrating strong data stewardship will accelerate clinical adoption and build stakeholder trust. Complementary investments in strategic partnerships, co-development agreements, and targeted regional expansion will ensure that organizations can scale responsibly while responding to localized market needs. These actions, taken together, will position industry leaders to capture long-term value despite short-term market turbulence.

A rigorous, multi-source research methodology combining primary stakeholder interviews, technical literature review, and analytical frameworks to validate trends and strategic implications

This research employed a multi-faceted methodology that combined primary stakeholder interviews, technical literature review, and systematic analysis of product and regulatory developments to ensure a comprehensive and balanced perspective. Primary engagements included conversations with R&D leaders, clinical laboratory directors, procurement specialists, and commercial leaders across instrument and reagent providers. These interactions were structured to elicit insights into operational challenges, adoption drivers, and strategic responses to evolving policy and supply chain conditions.

Secondary research involved the review of peer-reviewed journals, conference proceedings, patent filings, and public regulatory documents to validate technical trends and to trace the evolution of key technologies. Additionally, catalogues of product specifications, vendor disclosures, and publicly available case studies were synthesized to map feature differentials, integration capabilities, and deployment contexts. The methodology emphasized triangulation across sources to reduce bias and to reconcile differing perspectives on technology maturity and clinical readiness.

Analytical frameworks included segmentation mapping, scenario planning for supply chain risk, and evaluation of commercial models based on pricing, service scope, and customer support structures. Throughout, quality assurance processes were applied to check factual accuracy and to ensure that conclusions are supported by multiple independent inputs. The result is a rigorous evidence-based assessment designed to inform strategic planning and operational decision-making.

A conclusive synthesis emphasizing adaptability, technical integration, and governance as the decisive factors for sustained success in the evolving genomics ecosystem

The concluding synthesis reiterates that genomics is at an inflection point where technological capability, commercial innovation, and regulatory stewardship intersect to define future winners and laggards. Organizations that align investments in interoperable platforms, resilient supply chains, and outcome-driven services will create durable competitive advantages. Moreover, proactive engagement with regulatory and data governance issues will accelerate the translation of laboratory advances into clinical and commercial impact.

Looking ahead, the ability to translate complex data streams into actionable decisions-whether for therapeutic development, diagnostic deployment, or agricultural improvement-will distinguish high-performing organizations. Strategic partnerships, flexible business models, and a relentless focus on customer outcomes will enable firms to capture emerging opportunities while mitigating operational risks. The key message is that adaptability, technical excellence, and trustworthiness are the principal currencies in a rapidly changing genomics ecosystem.

In closing, this analysis provides a structured foundation for leaders to prioritize investments, shape product roadmaps, and refine commercial approaches. By focusing on the levers that most strongly influence adoption and value realization, organizations can navigate uncertainty and position themselves for sustainable impact in research, clinical care, and broader applied genomics contexts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genomics Market, by Product Type

  • 8.1. Microarrays
    • 8.1.1. Gene Expression Arrays
    • 8.1.2. SNP Genotyping Arrays
  • 8.2. PCR
    • 8.2.1. Digital PCR
    • 8.2.2. qPCR
  • 8.3. Reagents & Consumables
    • 8.3.1. Enzymes & Master Mixes
    • 8.3.2. Library Preparation Kits
    • 8.3.3. Probes & Primers
  • 8.4. Sequencing Services
    • 8.4.1. NGS Services
    • 8.4.2. Sanger Sequencing Services
  • 8.5. Sequencing Systems
    • 8.5.1. NGS Platforms
    • 8.5.2. Sanger Sequencers

9. Genomics Market, by Technology

  • 9.1. Array Technology
    • 9.1.1. Microarray Gene Expression
    • 9.1.2. SNP Genotyping Arrays
  • 9.2. DNA Sequencing
    • 9.2.1. Next-Generation Sequencing
    • 9.2.2. Sanger Sequencing
  • 9.3. PCR Technology
    • 9.3.1. Digital PCR
    • 9.3.2. qPCR
  • 9.4. RNA Sequencing
    • 9.4.1. Bulk RNA Sequencing
    • 9.4.2. Single-Cell RNA Sequencing

10. Genomics Market, by Application

  • 10.1. Agriculture
    • 10.1.1. Animal Genomics
    • 10.1.2. Crop Genomics
  • 10.2. Diagnostics
    • 10.2.1. Cancer Genomics
    • 10.2.2. Genetic Testing
    • 10.2.3. Infectious Disease Testing
  • 10.3. Drug Discovery & Development
    • 10.3.1. Biomarker Discovery
    • 10.3.2. Target Identification
  • 10.4. Personalized Medicine
    • 10.4.1. Companion Diagnostics
    • 10.4.2. Precision Therapeutics

11. Genomics Market, by End User

  • 11.1. Academic & Government Institutes
  • 11.2. Commercial Research Organizations
  • 11.3. Hospitals & Clinics
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Genomics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Genomics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Genomics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Genomics Market

16. China Genomics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 10x Genomics, Inc.
  • 17.6. Agilent Technologies, Inc.
  • 17.7. Azenta, Inc.
  • 17.8. BGI Genomics Co., Ltd.
  • 17.9. Bio-Rad Laboratories, Inc.
  • 17.10. Color Health, Inc.
  • 17.11. Eurofins Scientific SE
  • 17.12. F. Hoffmann-La Roche Ltd
  • 17.13. Fulgent Genetics, Inc.
  • 17.14. Guardant Health, Inc.
  • 17.15. Illumina, Inc.
  • 17.16. Invitae Corporation
  • 17.17. Myriad Genetics, Inc.
  • 17.18. Natera, Inc.
  • 17.19. Oxford Nanopore Technologies plc
  • 17.20. Pacific Biosciences of California, Inc.
  • 17.21. PerkinElmer, Inc.
  • 17.22. QIAGEN N.V.
  • 17.23. Thermo Fisher Scientific Inc.
  • 17.24. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENOMICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENOMICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENOMICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENOMICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENOMICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENOMICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENOMICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENOMICS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENOMICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENOMICS MARKET SIZE, BY ENZYMES & MASTER MIXES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENOMICS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENOMICS MARKET SIZE, BY PROBES & PRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENOMICS MARKET SIZE, BY NGS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENOMICS MARKET SIZE, BY NGS PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENOMICS MARKET SIZE, BY MICROARRAY GENE EXPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENOMICS MARKET SIZE, BY SNP GENOTYPING ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENOMICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENOMICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENOMICS MARKET SIZE, BY BULK RNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENOMICS MARKET SIZE, BY SINGLE-CELL RNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENOMICS MARKET SIZE, BY ANIMAL GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENOMICS MARKET SIZE, BY CROP GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENOMICS MARKET SIZE, BY CANCER GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENOMICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GENOMICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GENOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GENOMICS MARKET SIZE, BY PRECISION THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL GENOMICS MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENOMICS MARKET SIZE, BY COMMERCIAL RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL GENOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS GENOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. GLOBAL GENOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. ASEAN GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 312. ASEAN GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 313. ASEAN GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 314. ASEAN GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 315. ASEAN GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 316. ASEAN GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 317. ASEAN GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. GCC GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 319. GCC GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. GCC GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 321. GCC GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 322. GCC GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 323. GCC GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 324. GCC GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 325. GCC GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 326. GCC GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 327. GCC GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 328. GCC GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 329. GCC GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 330. GCC GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 331. GCC GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 332. GCC GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 333. GCC GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 334. GCC GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 335. GCC GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 336. EUROPEAN UNION GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. EUROPEAN UNION GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 340. EUROPEAN UNION GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 342. EUROPEAN UNION GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 343. EUROPEAN UNION GENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 344. EUROPEAN UNION GENOMICS MARKET SIZE, BY ARRAY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 345. EUROPEAN UNION GENOMICS MARKET SIZE, BY DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 346. EUROPEAN UNION GENOMICS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 347. EUROPEAN UNION GENOMICS MARKET SIZE, BY RNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 348. EUROPEAN UNION GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 349. EUROPEAN UNION GENOMICS MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 350. EUROPEAN UNION GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 351. EUROPEAN UNION GENOMICS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 352. EUROPEAN UNION GENOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 353. EUROPEAN UNION GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 354. BRICS GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 355. BRICS GENOMICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 356. BRICS GENOMICS MARKET SIZE, BY MICROARRAYS, 2018-2032 (USD MILLION)
  • TABLE 357. BRICS GENOMICS MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 358. BRICS GENOMICS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 359. BRICS GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 360. BRICS GENOMICS MARKET SIZE, BY SEQUENCING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 361. BR